PWM
ALNY icon

Parkworth Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Parkworth Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.3K Buy
4
+2
+100% +$553 ﹤0.01% 354
2025
Q1 		$540 Buy
2
+1
+100% +$257 ﹤0.01% 391
2024
Q4 		$235 Buy
+1
New +$263 ﹤0.01% 702

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parkworth Wealth Management's ALNY Position: Q2 2025 in Review

Parkworth Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 100% in Q2 2025, buying an estimated $553 and bringing the position to 4 shares worth $1.3K. The position accounts for ﹤0.01% of the portfolio, ranked #354.

Parkworth Wealth Management first reported a position in ALNY in Q4 2024 and has held it in 3 quarters since. 653 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Parkworth Wealth Management held 4 shares of Alnylam Pharmaceuticals worth $1.3K as of Q2 2025.
  • Parkworth Wealth Management bought 2 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $553.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #354 holding.
  • Parkworth Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • 653 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.